|
ES2313900T3
(es)
*
|
1999-07-28 |
2009-03-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nicotina en angiogenesis y vasculogenesis terapeutica.
|
|
US8914114B2
(en)
|
2000-05-23 |
2014-12-16 |
The Feinstein Institute For Medical Research |
Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
|
|
US6486172B2
(en)
|
2000-08-18 |
2002-11-26 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl compounds for treatment of disease
|
|
US6492385B2
(en)
|
2000-08-18 |
2002-12-10 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
|
US6479510B2
(en)
|
2000-08-18 |
2002-11-12 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl compounds for treatment of disease
|
|
WO2002017358A2
(en)
|
2000-08-21 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
|
|
US6599916B2
(en)
|
2000-08-21 |
2003-07-29 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
|
CA2341952A1
(en)
*
|
2001-03-23 |
2002-09-23 |
Universite Laval |
Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
|
|
US20050130990A1
(en)
*
|
2001-03-23 |
2005-06-16 |
Universite Laval |
Nicotinic receptor agonists for the treatment of inflammatory diseases
|
|
PE20021019A1
(es)
|
2001-04-19 |
2002-11-13 |
Upjohn Co |
Grupos azabiciclicos sustituidos
|
|
AR036040A1
(es)
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
|
|
AR036041A1
(es)
*
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
|
|
EP1419162A1
(en)
*
|
2001-08-24 |
2004-05-19 |
Pharmacia & Upjohn Company |
Substituted-aryl 7-aza 2.2.1]bicycloheptanes for the treatment of disease
|
|
BR0212101A
(pt)
|
2001-08-24 |
2004-08-24 |
Pharmacia & Up John Company |
7-aza [2.2.1] biciclo-heptanos substituìdos com heteroarila para o tratamento de doenças
|
|
JP2005527472A
(ja)
*
|
2001-09-12 |
2005-09-15 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
疾患治療のための置換された７−アザ［２．２．１］ビシクロヘプタン
|
|
HUP0402289A2
(hu)
|
2001-10-02 |
2005-02-28 |
Pharmacia & Upjohn Company |
Gyógyhatású azabiciklusos csoporttal helyettesített kondenzált heteroaril-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
|
|
US6919359B2
(en)
*
|
2001-11-08 |
2005-07-19 |
Pfizer Inc |
Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
|
|
US6951868B2
(en)
|
2001-11-09 |
2005-10-04 |
Pfizer Inc. |
Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease
|
|
EP1463481A4
(en)
*
|
2001-12-14 |
2008-06-25 |
Targacept Inc |
METHOD AND COMPOSITIONS FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM
|
|
DE10164139A1
(de)
|
2001-12-27 |
2003-07-10 |
Bayer Ag |
2-Heteroarylcarbonsäureamide
|
|
US6852741B2
(en)
*
|
2001-12-31 |
2005-02-08 |
University Of Florida |
Compositions and methods for treatment of neurological disorders
|
|
US6852716B2
(en)
|
2002-02-15 |
2005-02-08 |
Pfizer Inc |
Substituted-aryl compounds for treatment of disease
|
|
AU2003217275A1
(en)
*
|
2002-02-19 |
2003-09-09 |
Pharmacia And Upjohn Company |
Azabicyclic compounds for the treatment of disease
|
|
JP2005523288A
(ja)
*
|
2002-02-19 |
2005-08-04 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド
|
|
CA2475773A1
(en)
*
|
2002-02-20 |
2003-09-04 |
Pharmacia & Upjohn Company |
Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
|
|
US8039459B2
(en)
|
2004-07-15 |
2011-10-18 |
Universite Laval |
Nicotinic receptor agonists for the treatment of inflammatory diseases
|
|
US8557804B2
(en)
|
2002-03-25 |
2013-10-15 |
Universite Laval |
Nicotinic receptor agonists for the treatment of inflammatory diseases
|
|
EP1542999A1
(en)
*
|
2002-08-01 |
2005-06-22 |
Pharmacia & Upjohn Company LLC |
1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
|
|
JP2006501246A
(ja)
*
|
2002-08-30 |
2006-01-12 |
メモリー・ファーマシューティカルズ・コーポレイション |
神経変性疾患の治療において有用なアナバセイン誘導体
|
|
WO2004039815A2
(en)
*
|
2002-11-01 |
2004-05-13 |
Pharmacia & Upjohn Company Llc |
Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
|
|
DE10251963A1
(de)
*
|
2002-11-08 |
2004-05-19 |
Lts Lohmann Therapie-Systeme Ag |
Transmucosale pharmazeutische Darreichungsform
|
|
US7238715B2
(en)
*
|
2002-12-06 |
2007-07-03 |
The Feinstein Institute For Medical Research |
Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
|
|
WO2004052365A2
(en)
|
2002-12-06 |
2004-06-24 |
North Shore-Long Island Jewish Research Institute |
Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists
|
|
WO2005023942A2
(en)
*
|
2003-02-20 |
2005-03-17 |
University Of Florida |
Materials and methods for inhibiting fouling of surfaces exposed to aquatic environments
|
|
US8580842B2
(en)
|
2003-09-30 |
2013-11-12 |
Abbott Gmbh & Co. Kg |
Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
|
|
US8729129B2
(en)
|
2004-03-25 |
2014-05-20 |
The Feinstein Institute For Medical Research |
Neural tourniquet
|
|
US10912712B2
(en)
|
2004-03-25 |
2021-02-09 |
The Feinstein Institutes For Medical Research |
Treatment of bleeding by non-invasive stimulation
|
|
WO2005123075A2
(en)
*
|
2004-06-08 |
2005-12-29 |
University Of Florida Research Foundation, Inc. |
Controlling angiogenesis with anabaseine analogs
|
|
CN102793972A
(zh)
|
2004-12-27 |
2012-11-28 |
范因斯坦医学研究院 |
通过电刺激迷走神经治疗炎症性疾病
|
|
US11207518B2
(en)
|
2004-12-27 |
2021-12-28 |
The Feinstein Institutes For Medical Research |
Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
|
|
WO2006133303A1
(en)
*
|
2005-06-07 |
2006-12-14 |
University Of Florida Research Foundation, Inc. |
Alpha 7 nicotinic receptor selective ligands
|
|
US8316104B2
(en)
|
2005-11-15 |
2012-11-20 |
California Institute Of Technology |
Method and apparatus for collaborative system
|
|
US7662965B2
(en)
|
2006-01-26 |
2010-02-16 |
Cornerstone Therapeutics, Inc. |
Anabaseine derivatives, pharmaceutical compositions and method of use thereof
|
|
US20080167286A1
(en)
|
2006-12-12 |
2008-07-10 |
Abbott Laboratories |
Pharmaceutical compositions and their methods of use
|
|
US8486979B2
(en)
*
|
2006-12-12 |
2013-07-16 |
Abbvie Inc. |
1,2,4 oxadiazole compounds and methods of use thereof
|
|
UY30846A1
(es)
*
|
2006-12-30 |
2008-07-31 |
Abbott Gmbh & Amp |
Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
|
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
|
US8391970B2
(en)
|
2007-08-27 |
2013-03-05 |
The Feinstein Institute For Medical Research |
Devices and methods for inhibiting granulocyte activation by neural stimulation
|
|
KR20100097195A
(ko)
*
|
2007-12-07 |
2010-09-02 |
애보트 게엠베하 운트 콤파니 카게 |
５－할로겐－치환된 옥스인돌 유도체 및 바소프레신－의존성 질병을 치료하기 위한 이의 용도
|
|
EP2231644B1
(de)
|
2007-12-07 |
2014-01-15 |
AbbVie Deutschland GmbH & Co KG |
5,6-Disubstitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
|
|
JP5701607B2
(ja)
|
2007-12-07 |
2015-04-15 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
|
|
WO2010009775A1
(de)
|
2007-12-07 |
2010-01-28 |
Abbott Gmbh & Co. Kg |
Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
|
|
US8383657B2
(en)
|
2007-12-21 |
2013-02-26 |
Abbott Laboratories |
Thiazolylidine urea and amide derivatives and methods of use thereof
|
|
US9662490B2
(en)
|
2008-03-31 |
2017-05-30 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
|
|
WO2009146031A1
(en)
*
|
2008-03-31 |
2009-12-03 |
University Of South Florida |
Methods of treating disease-induced ataxia and non-ataxic imbalance
|
|
US9211409B2
(en)
|
2008-03-31 |
2015-12-15 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation of T-cell activity
|
|
ES2452484T3
(es)
|
2008-11-18 |
2014-04-01 |
Setpoint Medical Corporation |
Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
|
|
KR20180011888A
(ko)
|
2008-11-19 |
2018-02-02 |
포럼 파마슈티칼즈 인크. |
(ｒ)-７-클로로-ｎ-(퀴누클리딘-３-일)벤조［ｂ］티오펜-２-카르복사미드 및 그 약학적으로 허용가능한 염을 이용한 인지 장애의 치료
|
|
TW201031664A
(en)
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
|
US8996116B2
(en)
|
2009-10-30 |
2015-03-31 |
Setpoint Medical Corporation |
Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
|
|
US9211410B2
(en)
|
2009-05-01 |
2015-12-15 |
Setpoint Medical Corporation |
Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
|
PE20120324A1
(es)
*
|
2009-05-11 |
2012-04-17 |
Envivo Pharmaceuticals Inc |
Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos
|
|
EP2435080A2
(en)
|
2009-05-29 |
2012-04-04 |
Abbott Laboratories |
Pharmaceutical compositions for the treatment of pain
|
|
WO2010144578A2
(en)
|
2009-06-09 |
2010-12-16 |
Setpoint Medical Corporation |
Nerve cuff with pocket for leadless stimulator
|
|
US9833621B2
(en)
|
2011-09-23 |
2017-12-05 |
Setpoint Medical Corporation |
Modulation of sirtuins by vagus nerve stimulation
|
|
WO2014169145A1
(en)
|
2013-04-10 |
2014-10-16 |
Setpoint Medical Corporation |
Closed-loop vagus nerve stimulation
|
|
CN105126248B
(zh)
|
2009-12-23 |
2018-06-12 |
赛博恩特医疗器械公司 |
用于治疗慢性炎症的神经刺激设备和系统
|
|
AR081402A1
(es)
|
2010-05-17 |
2012-08-29 |
Envivo Pharmaceuticals Inc |
Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato
|
|
EP2611788B1
(en)
|
2010-09-03 |
2017-04-12 |
University of Florida Research Foundation, Incorporated |
Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
|
|
US12172017B2
(en)
|
2011-05-09 |
2024-12-24 |
Setpoint Medical Corporation |
Vagus nerve stimulation to treat neurodegenerative disorders
|
|
EP2707094B1
(en)
|
2011-05-09 |
2016-02-03 |
Setpoint Medical Corporation |
Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
|
US9572983B2
(en)
|
2012-03-26 |
2017-02-21 |
Setpoint Medical Corporation |
Devices and methods for modulation of bone erosion
|
|
CA2872005A1
(en)
|
2012-05-08 |
2013-11-14 |
Forum Pharmaceuticals, Inc. |
Methods of maintaining, treating or improving cognitive function
|
|
US11311725B2
(en)
|
2014-10-24 |
2022-04-26 |
Setpoint Medical Corporation |
Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
|
|
US11406833B2
(en)
|
2015-02-03 |
2022-08-09 |
Setpoint Medical Corporation |
Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
|
|
US10596367B2
(en)
|
2016-01-13 |
2020-03-24 |
Setpoint Medical Corporation |
Systems and methods for establishing a nerve block
|
|
US11471681B2
(en)
|
2016-01-20 |
2022-10-18 |
Setpoint Medical Corporation |
Batteryless implantable microstimulators
|
|
US10314501B2
(en)
|
2016-01-20 |
2019-06-11 |
Setpoint Medical Corporation |
Implantable microstimulators and inductive charging systems
|
|
CN108882885A
(zh)
|
2016-01-20 |
2018-11-23 |
赛博恩特医疗器械公司 |
迷走神经刺激的控制
|
|
US10583304B2
(en)
|
2016-01-25 |
2020-03-10 |
Setpoint Medical Corporation |
Implantable neurostimulator having power control and thermal regulation and methods of use
|
|
WO2018064529A1
(en)
|
2016-09-29 |
2018-04-05 |
The Uab Research Foundation |
Methods and compositions for increasing mucus clearance
|
|
US11173307B2
(en)
|
2017-08-14 |
2021-11-16 |
Setpoint Medical Corporation |
Vagus nerve stimulation pre-screening test
|
|
US11660443B2
(en)
|
2018-04-20 |
2023-05-30 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
|
|
US20210255202A1
(en)
|
2018-06-13 |
2021-08-19 |
Michael R. D'Andrea |
Methods and dosing regimens for preventing or delaying onset of alzheimer's disease and other forms of dementia and mild congnitive impairment
|
|
US11260229B2
(en)
|
2018-09-25 |
2022-03-01 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
|
|
US12343535B2
(en)
|
2019-04-12 |
2025-07-01 |
Setpoint Medical Corporation |
Vagus nerve stimulation to treat neurodegenerative disorders
|
|
AU2021207815B2
(en)
|
2020-01-13 |
2026-03-26 |
The Feinstein Institutes For Medical Research |
Treating bleeding and bleeding disorders via high intensity focused ultrasound stimulation of the spleen
|
|
US11938324B2
(en)
|
2020-05-21 |
2024-03-26 |
The Feinstein Institutes For Medical Research |
Systems and methods for vagus nerve stimulation
|
|
GB2612481A
(en)
*
|
2020-06-09 |
2023-05-03 |
Fadly Abd El Ghany Elkazaz Mohamed |
A novel medicament for immune modulation and treating chronic or hyper inflammation
|
|
WO2022245878A1
(en)
|
2021-05-17 |
2022-11-24 |
Setpoint Medical Corporation |
Neurostimulation parameter authentication and expiration system for neurostimulation
|
|
US20250229086A1
(en)
|
2022-01-20 |
2025-07-17 |
Setpoint Medical Corporation |
Treatment of inflammatory disorders
|